The short version of thymus extract fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-08 and is reviewed periodically as new material appears.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
| Property | Value | Notes |
|---|---|---|
| Detection wavelength | 214 nm | Peptide bond absorption; 280 nm is not useful. |
| Confirmatory method | Electrospray mass spectrometry | Verifies mass near 3108 Da. |
| Solution stability | Limited at room temperature | Aqueous solutions degrade faster than powder. |
| Recommended storage | -20 °C | For lyophilized powder; protect from moisture. |
| Purity criterion | ≥95% by RP-HPLC | Typical research-grade specification. |
=== Electrical === In electrical FFF a transverse electrical current (DC) is applied which creates an electric field. Depending on the charge of sample components, an electrophoretic drift velocity is induced, counteracted by the diffusion from Brownian motion, so the separation depends on the ratio of electrophoretic mobility and size. Application of electrical FFF has been limited and is currently rarely used. Other modifications have been developed, namely cyclical electrical FFF where a special alternating current is applied. It allows to separate according to electrophoretic mobility. Another variation is electrical asymmetrical flow FFF (EAF4), where an electrical field is applied in addition to a cross flow field. EAF4 overcomes the limitation of pure electrical FFF which has poor resolution and suffers from electrolysis products and bubbles contaminating the channel outflow and compromising the detector signals.
Coordination complexes have been known since the beginning of modern chemistry. Early well-known coordination complexes include dyes such as Prussian blue. Their properties were first well understood in the late 1800s, following the 1869 work of Christian Wilhelm Blomstrand. Blomstrand developed what has come to be known as the complex ion chain theory. In considering metal amine complexes, he theorized that the ammonia molecules compensated for the charge of the ion by forming chains of the type [(NH3)X]X+, where X is the coordination number of the metal ion. He compared his theoretical ammonia chains to hydrocarbons of the form (CH2)X. Following this theory, Danish scientist Sophus Mads Jørgensen made improvements to it. In his version of the theory, Jørgensen claimed that when a molecule dissociates in a solution there were two possible outcomes: the ions would bind via the ammonia chains Blomstrand had described or the ions would bind directly to the metal. It was not until 1893 that the most widely accepted version of the theory today was published by Alfred Werner. Werner's work included two important changes to the Blomstrand theory. The first was that Werner described the two possibilities in terms of location in the coordination sphere. He claimed that if the ions were to form a chain, this would occur outside of the coordination sphere while the ions that bound directly to the metal would do so within the coordination sphere. In one of his most important discoveries however Werner disproved the majority of the chain theory.
Difluoroescaline (DFE), also known as 4-(2,2-difluoroethoxy)-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline. It is a difluorinated derivative of escaline. Its dose range is 40 to 80 mg and its duration is 6 to 12 hours. The drug's effects include color enhancement, some closed-eye and open-eye visuals, emotional changes, and some physical discomfort. It acts as a low-potency partial agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors and targets. The chemical synthesis of difluoroescaline has been described. Difluoroescaline was first described in the scientific literature by Daniel Trachsel in 2002. Its pharmacology was studied in more detail in 2021. It is not a controlled substance in Canada as of 2025.
Sources: en.wikipedia.org
The final step in the non-mevalonate pathway is carried out by the enzyme 4-hydroxy-3-methylbut-2-enyl diphosphate reductase, which gives a mixture of dimethylallyl pyrophosphate and isopentenyl pyrophosphate in the ratio of five to one. The products are then used in terpenoid biosynthesis. HMB-PP is an essential metabolite in most pathogenic bacteria including Mycobacterium tuberculosis as well as in malaria parasites, but is absent from the human host. HMB-PP is the physiological activator ("phosphoantigen") for human Vγ9/Vδ2 T cells, the major γδ T cell population in peripheral blood. With a bioactivity of 0.1 nM it is 10,000-10,000,000 times more potent than any other natural compound, such as IPP or alkyl amines. HMB-PP functions in this capacity by binding the B30.2 domain of BTN3A1. 4-hydroxy-3-methylbut-2-enyl+pyrophosphate at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
CCL7 was first characterized from osteosarcoma supernatant. CCL7 consists of 99 amino acids, which contains 23-amino acid signal peptide. The mature protein about 76 amino acids is secreted after cleavage of the signal peptide. In contrast to most chemokines, CCL7 exists in a general monomeric form, differing from the dimer formed in a highly concentrated solution. CCL7 can exist in four different glycotypes with a molecular weight 11, 13, 17 and 18 kDa in COS cells. CCL7 mediates effects on the immune cell types through binding to numerous receptors, including CCR1, CCR2, CCR3, CCR5, and CCR10. These receptors belongs to the G protein-coupled seven-transmembrane receptors. CCL7 can also interact with cell surface glycosaminoglycans (GAGs) present on all animal cell surfaces.
81. ArXiv [Preprint]. 2026 Jul 29:arXiv:2605.17186v2. Operator splitting for exploiting linear-rate closure in solving infinite ODE hierarchies. Chang JC. We introduce an operator-splitting method for infinite hierarchies of linear ordinary differential equations (ODEs) indexed by nonnegative integers. When the coupling coefficients depend linearly on the count index, an exact transformation closes the equations on finite count-index windows without an upper-boundary value. For more general hierarchies, Strang splitting applies the linear-rate closure during the linear-rate substeps and a conventional capped solver to the remainder. We derive the closure from generating functions and the method of characteristics and extend it to multi-indexed systems. The derivation requires neither positivity nor mass conservation, so it applies to a wider class of systems than the examplar stochastic models presented here. We discuss branching processes, stochastic predator-prey dynamics, the Schlögl chemical kinetics model, and a telegraph model for gene expression. Through numerical experiments and computational cost analyses we demonstrate that our operator splitting method is typically advantageous for solving large scale systems in terms of memory usage and computational time, while retaining accuracy competitive with finite state projection (FSP) methods. PMCID: PMC13618430
Glycine is found at almost every third residue. Proline makes up about 17% of collagen. Collagen contains two unusual derivative amino acids not directly inserted during translation. These amino acids are found at specific locations relative to glycine and are modified post-translationally by different enzymes, both of which require vitamin C as a cofactor. Hydroxyproline derived from proline Hydroxylysine derived from lysine – depending on the type of collagen, varying numbers of hydroxylysines are glycosylated (mostly having disaccharides attached). Cortisol stimulates degradation of (skin) collagen into amino acids.
Sources: en.wikipedia.org
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.
The lyophilized powder is usually stored at -20 °C or below. Dissolved solutions are less stable and should be prepared fresh when possible. Freeze-thaw cycling can reduce integrity.
It lacks aromatic residues, so it does not absorb strongly at 280 nm. Its negative charge and hydrophilic nature can affect chromatographic retention. These properties require method development for reliable separation.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.